Creative Medical Technology Holdings Inc (NASDAQ:CELZ) shares are trading higher Wednesday after the company announced top-line results for its follow-up StemSpine pilot study.
The initial study showed significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects.
In the follow-up study two years later, there were no safety related concerns and the StemSpine procedure resulted in an efficacy rate of 87% in the treated patients.
StemSpine is a patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain.
Creative Medical Technology Holdings is a biotechnology holding company focused on regenerative medicine.
See Also: Why Allego Shares Are Surging
CELZ 52-Week Range: $0.01 - $9.00
The stock was up 84.1% at $3.12 at publication time.
Photo: Belova59 from Pixabay.
